Latest Quinazolines Stories
Drug resistant lung cancer cells change their behavior in ways we do not understand to evade treatment, but these events can now be recapitulated and studied in mice.
UH Case Medical Center study in JCO reinforces focus on personalized treatment for patients based on ethnicity.
Use of the molecularly targeted agent lapatinib to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients.
NEW YORK, Sept.
NEW YORK, Sept.
SYDNEY, Aug. 5 /PRNewswire/ -- Rising public awareness of breast cancer and available treatments have increased revenues in the breast cancer therapeutics market in Australia.
RIDGEFIELD, Conn., Aug.
Previously untreated non-small cell lung cancer (NSCLC) patients over the age of 70 respond well to a combination of bevacizumab and erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.
Non-small cell lung cancer patients who have progressed on a cetuximab-containing regimen may respond to erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.
WILMINGTON, Del., July 30 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the company has submitted a New Drug Application to the U.S.
- A pivoted catch designed to fall into a notch on a ratchet wheel so as to allow movement in only one direction (e.g. on a windlass or in a clock mechanism), or alternatively to move the wheel in one direction.